Harshita B. Gupta

981 total citations
28 papers, 726 citations indexed

About

Harshita B. Gupta is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Harshita B. Gupta has authored 28 papers receiving a total of 726 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 19 papers in Immunology and 4 papers in Epidemiology. Recurrent topics in Harshita B. Gupta's work include Cancer Immunotherapy and Biomarkers (21 papers), Immune Cell Function and Interaction (12 papers) and Immunotherapy and Immune Responses (11 papers). Harshita B. Gupta is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Immune Cell Function and Interaction (12 papers) and Immunotherapy and Immune Responses (11 papers). Harshita B. Gupta collaborates with scholars based in United States, Switzerland and China. Harshita B. Gupta's co-authors include Tyler J. Curiel, Curtis A. Clark, Álvaro Padrón, Vincent Hurez, Bin Yuan, Ratna K. Vadlamudi, Rong Li, José R. Conejo-García, Srilakshmi Pandeswara and Justin Drerup and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Cancer Research.

In The Last Decade

Harshita B. Gupta

26 papers receiving 723 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harshita B. Gupta United States 11 470 379 231 102 80 28 726
Curtis A. Clark United States 11 392 0.8× 334 0.9× 218 0.9× 77 0.8× 68 0.8× 21 740
Omar Elaskalani Australia 8 246 0.5× 198 0.5× 240 1.0× 36 0.4× 99 1.2× 11 568
Trisha R. Sippel United States 11 253 0.5× 422 1.1× 180 0.8× 40 0.4× 94 1.2× 11 687
Carmen M. Anadon United States 10 195 0.4× 187 0.5× 334 1.4× 67 0.7× 141 1.8× 18 634
Lai Chun Ong Singapore 5 297 0.6× 173 0.5× 171 0.7× 66 0.6× 100 1.3× 5 546
Sara Danielli United Kingdom 7 181 0.4× 302 0.8× 193 0.8× 99 1.0× 64 0.8× 9 528
Samantha Lasser Germany 9 284 0.6× 427 1.1× 236 1.0× 28 0.3× 105 1.3× 11 697
Ihor Arkhypov Germany 10 286 0.6× 402 1.1× 228 1.0× 26 0.3× 101 1.3× 11 677
Xuefeng Hua China 9 317 0.7× 317 0.8× 195 0.8× 64 0.6× 148 1.9× 21 691

Countries citing papers authored by Harshita B. Gupta

Since Specialization
Citations

This map shows the geographic impact of Harshita B. Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harshita B. Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harshita B. Gupta more than expected).

Fields of papers citing papers by Harshita B. Gupta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harshita B. Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harshita B. Gupta. The network helps show where Harshita B. Gupta may publish in the future.

Co-authorship network of co-authors of Harshita B. Gupta

This figure shows the co-authorship network connecting the top 25 collaborators of Harshita B. Gupta. A scholar is included among the top collaborators of Harshita B. Gupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harshita B. Gupta. Harshita B. Gupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tang, Jian, Ramkumar Moorthy, Özlem Demir, et al.. (2025). Targeting N-Myc in neuroblastoma with selective Aurora kinase A degraders. Cell chemical biology. 32(2). 352–362.e10. 6 indexed citations
2.
Argyris, Prokopios P., Michael A. Carpenter, Harshita B. Gupta, et al.. (2023). DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo. International Journal of Molecular Sciences. 24(11). 9305–9305. 8 indexed citations
3.
Kumari, Diksha, Harshita B. Gupta, Deepika Chauhan, et al.. (2023). Flow cytometry profiling of cellular immune response in COVID-19 infected, recovered and vaccinated individuals. Immunobiology. 228(3). 152392–152392. 4 indexed citations
4.
Padrón, Álvaro, Yilun Deng, Yiji Liao, et al.. (2023). Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects. Journal for ImmunoTherapy of Cancer. 11(2). e004871–e004871. 8 indexed citations
5.
Deng, Yilun, Clare Murray, Álvaro Padrón, et al.. (2022). Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. SHILAP Revista de lepidopterología. 3(1). 68–83. 16 indexed citations
6.
Zhang, Deyi, Harshita B. Gupta, Álvaro Padrón, et al.. (2021). Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Medicine. 10(6). 2137–2152. 34 indexed citations
7.
Deng, Yilun, Deyi Zhang, Niannian Ji, et al.. (2021). CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. Journal for ImmunoTherapy of Cancer. 9(4). e002051–e002051. 14 indexed citations
8.
Kornepati, Anand, Clare Murray, Cody M. Rogers, et al.. (2021). 900 Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner. SHILAP Revista de lepidopterología. A944–A944. 2 indexed citations
9.
Drerup, Justin, Yilun Deng, Álvaro Padrón, et al.. (2020). CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Research. 80(22). 5063–5075. 27 indexed citations
10.
Deng, Yilun, Justin Drerup, Xinyue Zhang, et al.. (2020). 690 CD122-selective IL-2 complexes treat ovarian carcinomas, induce Treg fragility and promote T cell stem cells. SHILAP Revista de lepidopterología. A414–A415. 2 indexed citations
11.
Wu, Bogang, Xiujie Sun, Bin Yuan, et al.. (2020). PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner. International Journal of Biological Sciences. 16(9). 1526–1535. 17 indexed citations
12.
Gupta, Harshita B., et al.. (2019). Tumor-intrinsic PD-L1 reduces actin cytoskeleton polymerization to promote mTORC1 signals driving tumor stemness. The Journal of Immunology. 202(1_Supplement). 137.8–137.8. 1 indexed citations
13.
Gupta, Harshita B., Clare Murray, Xinyue Zhang, et al.. (2019). Tumor-intrinsic PD-L1 regulates tumor initiating cell virulence and stemness genes, and TCF1+ stem-like T cells through Raptor in ovarian cancer, which correlates with survival in high grade serous ovarian cancer. The Journal of Immunology. 202(1_Supplement). 195.29–195.29. 1 indexed citations
14.
Wu, Bogang, Xiujie Sun, Harshita B. Gupta, Tyler J. Curiel, & Rong Li. (2019). Adipocyte PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Cancer Immunotherapy Efficacy. The Journal of Immunology. 202(1_Supplement). 195.16–195.16. 1 indexed citations
15.
Padrón, Álvaro, Vincent Hurez, Harshita B. Gupta, et al.. (2018). Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Experimental Gerontology. 105. 146–154. 33 indexed citations
16.
Wu, Bogang, Xiujie Sun, Harshita B. Gupta, et al.. (2018). Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. OncoImmunology. 7(11). e1500107–e1500107. 76 indexed citations
17.
Gupta, Harshita B., et al.. (2018). Tumor cell-intrinsic programmed death protein 1 expression and induction in human cancer cell lines. The Journal of Immunology. 200(Supplement_1). 178.33–178.33. 2 indexed citations
18.
Clark, Curtis A., Harshita B. Gupta, Gangadhara R. Sareddy, et al.. (2016). Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Research. 76(23). 6964–6974. 309 indexed citations
19.
Gupta, Harshita B., Curtis A. Clark, Bin Yuan, et al.. (2016). Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduction and Targeted Therapy. 1(1). 94 indexed citations
20.
Gupta, Harshita B., Vincent Hurez, Curtis A. Clark, et al.. (2016). Tumor B7-H1 regulates cancer stem cell generation and virulence. The Journal of Immunology. 196(1_Supplement). 72.3–72.3. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Curtis A. Clark Breakdown of academic impact, for papers by Omar Elaskalani Breakdown of academic impact, for papers by Trisha R. Sippel Breakdown of academic impact, for papers by Carmen M. Anadon Breakdown of academic impact, for papers by Lai Chun Ong Breakdown of academic impact, for papers by Sara Danielli Breakdown of academic impact, for papers by Samantha Lasser Breakdown of academic impact, for papers by Ihor Arkhypov Breakdown of academic impact, for papers by Xuefeng Hua
Rankless by CCL
2026